The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per patient per trial. This is very mundane and very hard, arduous work. We ...
Ocular Surface Disease | Clinical | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, ...
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Danon disease has been misclassified as cone dystrophy, cone-rod dystrophy, or retinitis pigmentosa; distinguishing features include the absence of optic disc pallor, bone-spicule pigmentation, and a ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with reassuring safety. On safety, the company said 4D-150 continues to be well ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results